The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Protein-protein interactions govern a large number of biological processes. A number of cell surface and nuclear receptors mediate their actions via dimerization. While this has been well ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Cobenfy, targeting M1 and M4 muscarinic receptors, represents a significant advancement. Unlike traditional antipsychotics, which block dopamine receptors, this approach effectively reduces both ...

Xanomeline was first developed in the 1990s and trialed in patients with Alzheimer’s disease, appearing to improve cognitive function ... Trospium is a muscarinic receptor-blocking drug that ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...